JP2011012060A5 - - Google Patents

Download PDF

Info

Publication number
JP2011012060A5
JP2011012060A5 JP2010147994A JP2010147994A JP2011012060A5 JP 2011012060 A5 JP2011012060 A5 JP 2011012060A5 JP 2010147994 A JP2010147994 A JP 2010147994A JP 2010147994 A JP2010147994 A JP 2010147994A JP 2011012060 A5 JP2011012060 A5 JP 2011012060A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antitrypsin
alpha
treatment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010147994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011012060A (ja
JP5231490B2 (ja
Filing date
Publication date
Priority claimed from ES200930387A external-priority patent/ES2332645B1/es
Application filed filed Critical
Publication of JP2011012060A publication Critical patent/JP2011012060A/ja
Publication of JP2011012060A5 publication Critical patent/JP2011012060A5/ja
Application granted granted Critical
Publication of JP5231490B2 publication Critical patent/JP5231490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010147994A 2009-06-30 2010-06-29 慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用 Active JP5231490B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (3)

Publication Number Publication Date
JP2011012060A JP2011012060A (ja) 2011-01-20
JP2011012060A5 true JP2011012060A5 (enExample) 2011-03-31
JP5231490B2 JP5231490B2 (ja) 2013-07-10

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010147994A Active JP5231490B2 (ja) 2009-06-30 2010-06-29 慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用

Country Status (16)

Country Link
US (1) US9205134B2 (enExample)
EP (1) EP2289540B1 (enExample)
JP (1) JP5231490B2 (enExample)
CN (1) CN101934071B (enExample)
AR (1) AR077123A1 (enExample)
AU (1) AU2010202203B2 (enExample)
BR (1) BRPI1002087B1 (enExample)
CA (1) CA2706212C (enExample)
CL (1) CL2010000575A1 (enExample)
ES (2) ES2332645B1 (enExample)
MX (1) MX2010006125A (enExample)
NZ (1) NZ585890A (enExample)
PL (1) PL2289540T3 (enExample)
PT (1) PT2289540E (enExample)
RU (1) RU2436590C1 (enExample)
UY (1) UY32670A (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793936A4 (en) * 2011-12-19 2015-05-27 Lfb Usa Inc RECOMBINANT HUMAN ALPHA-1-ANTITRYPINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CA2405565A1 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
US20040043510A1 (en) * 2000-07-14 2004-03-04 Nobuyuki Shigetoh Particle-labeled protein and immuno-chromatograph using the same
EP1562621B1 (en) 2002-11-20 2009-08-19 Arriva-Prometic Inc. Composition for treating ichthyosis using antitrypsin
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
JP2007504144A (ja) * 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
KR20100087291A (ko) * 2007-09-25 2010-08-04 아보트 러보러터리즈 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물
EP2214699B1 (en) 2007-11-02 2016-11-30 Grifols Therapeutics Inc. Method, composition, and article of manufacture for providing alpha-1 antitrypsin

Similar Documents

Publication Publication Date Title
JP2013520405A5 (enExample)
EP2749280A3 (en) Combination of glycopyrronium and formoterol
JP2012092110A5 (enExample)
JP2015517983A5 (enExample)
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
JP2015517488A5 (enExample)
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
JP2014503593A5 (enExample)
PE20150171A1 (es) Nueva forma de dosificacion y formulacion de abediterol
JP2013533269A5 (enExample)
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
JP2014532722A5 (enExample)
WO2013058484A3 (ko) 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
JP2011012060A5 (enExample)
MA34084B1 (fr) Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.